China Medical System Holdings Limited (the Company, together with its subsidiaries, the Group) announced a Distribution Agreement with Novartis Pharma Services AG on 27 October 2025. Under this agreement, the Group has obtained the exclusive right to import, distribute, sell, and promote Ranibizumab Injection (Lucentis®) and Brolucizumab Injection (Beovu®) in mainland China for five years, starting from the effective date of the contract. Novartis will continue to be responsible for production and supply.

Lucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting vascular endothelial growth factor A. It was introduced in China in 2011 and has received approval for multiple ocular neovascular conditions, including age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity, among others. It was included in the National Reimbursement Drug List in 2017 and has accumulated significant clinical application experience.

Beovu® is a novel anti-VEGF-A humanized single-chain antibody fragment approved in May 2025 in China for diabetic macular edema (DME). With a smaller molecular weight of 26 kDa, Beovu® requires injections once every six weeks during the loading phase. Global Phase 3 studies and real-world data in China have shown sustained visual benefits, reduced intraretinal and subretinal fluid, and fewer required injections compared to other anti-VEGF therapies.

Through this collaboration, the Group’s ophthalmology company, CMS Vision, will enhance its competitiveness by integrating Lucentis® and Beovu® into a product portfolio that already includes Augentropfen Stulln Mono Eye Drops and the EyeOP1 Glaucoma Treatment Device. The addition of these treatments is expected to bring synergy in customer resources and marketing channels, further strengthening CMS Vision’s academic brand while presenting more therapeutic options for patients. According to the announcement, the agreement is on normal commercial terms and is anticipated to have a positive impact on the Group’s financial results.